Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity

Journal of Investigative Dermatology

Volumn 129, Issue 2, 2009, Pages 383-391

  Boyle, Glen M ^a,d   Pedley, Julie ^a   Martyn, Adam C ^a   Banducci, Kelly J ^a   Strutton, Geoffrey M ^b   Brown, David A ^c   Breit, Samuel N ^c   Parsons, Peter G ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA;

ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN CARCINOGENESIS; TUMOR BIOPSY; TUMOR PROMOTION; ULTRAVIOLET IRRADIATION;

BIOPSY; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MELANOCYTES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SKIN NEOPLASMS; TRANSCRIPTION, GENETIC; ULTRAVIOLET RAYS;

EID: 58449129853     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.270     Document Type: Article

References (56)

1. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF et al. (2002) Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 21:4212-9
2. Baek SJ, Horowitz JM, Eling TE (2001a) Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 276:33384-92
3. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE (2005) Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 67:356-64
4. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE (2001b) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:901-8
5. Baek SJ, Wilson LC, Eling TE (2002) Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23: 425-434
6. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M et al. (2005) The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 65:2330-6
7. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M et al. (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66:4983-6
8. Bauskin AR, Zhang HP, Fairlie WD, He XY, Russell PK, Moore AG et al. (2000) The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J 19:2212-20
9. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P et al. (2001) Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res 61: 8306-8316
10. Bottner M, Laaff M, Schechinger B, Rappold G, Unsicker K, Suter-Crazzolara C (1999a) Characterization of the rat, mouse, and human genes of growth/ differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/ MIC-1). Gene 237:105-11
11. Bottner M, Suter-Crazzolara C, Schober A, Unsicker K (1999b) Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res 297:103-10
12. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ et al. (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9:2642-50
13. Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L et al. (2001) Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 61:6996-7001
14. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B et al. (2005) Hypoxia-inducible factor 1\{alpha\} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170:49-59
15. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L et al. (2005) Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433:764-9
16. Chen TR (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104:255-62
17. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-5
18. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117-29
19. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE et al. (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565-76
20. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22
21. Goding CR (2000) Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 14:1712-28
22. Graichen R, Liu D, Sun Y, Lee KO, Lobie PE (2002) Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells. J Biol Chem 277:26662-72
23. Halachmi S, Gilchrest BA (2001) Update on genetic events in the pathogenesis of melanoma. Curr Opin Oncol 13:129-36
24. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE (1998) MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391:298-301
25. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L (1997) PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1354:40-4
26. Jemal A, Devesa SS, Hartge P, Tucker MA (2001) Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 93:678-83
27. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK (2002) Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23:967-75
28. Krasagakis K, Kruger-Krasagakes S, Fimmel S, Eberle J, Tholke D, von der Ohe M et al. (1999) Desensitization of melanoma cells to autocrine TGF-beta isoforms. J Cell Physiol 178:179-87
29. Lawton LN, Bonaldo MF, Jelenc PC, Qiu L, Baumes SA, Marcelino RA et al. (1997) Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene 203:17-26
30. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM et al. (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648-55
31. Leonard JH, Cook AL, Van Gele M, Boyle GM, Inglis KJ, Speleman F et al. (2002) Proneural and proneuroendocrine transcription factor expression in cutaneous mechanoreceptor (Merkel) cells and Merkel cell carcinoma. Int J Cancer 101:103-10
32. Leonard JH, Marks LH, Chen W, Cook AL, Boyle GM, Smit DJ et al. (2003) Screening of human primary melanocytes of defined melanocortin-1 receptor genotype: pigmentation marker, ultrastructural and UV-survival studies. Pigment Cell Res 16:198-207
33. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C et al. (2000) Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275:20127-35
34. Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B et al. (2004) H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 96:1248-54
35. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ et al. (2003) Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63:5034-40
36. Loercher AE, Tank EM, Delston RB, Harbour JW (2005) MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 168:35-40
37. McGill GG, Haq R, Nishimura EK, Fisher DE (2006) c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 281:10365-73
38. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK et al. (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109:707-18
39. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S et al. (1998) Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 273:13760-7
40. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM et al. (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23:4060-7
41. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
42. Reed JA, McNutt NS, Prieto VG, Albino AP (1994) Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 145:97-104
43. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe C et al. (1994) Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54:575-81
44. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK (2005) Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448-56
45. Schmid P, Itin P, Rufli T (1995) In situ analysis of transforming growth factorbeta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16: 1499-1503
46. Smythe G (2006) statmod. Statistical Modeling. R package version 1.2.4
47. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J et al. (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11:7234-42
48. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687-701
49. Vance KW, Goding CR (2004) The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 17:318-25
50. Watari A, Takaki K, Higashiyama S, Li Y, Satomi Y, Takao T et al. (2006) Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. Oncogene 25:7373-80
51. Weinstock MA (2000) Early detection of melanoma. JAMA 284:886-9
52. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR et al. (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 100:3410-5
53. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA et al. (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61:5974-8
54. Xu C, Green A, Parisi A, Parsons PG (2001) Photosensitization of the sunscreen octyl p-dimethylaminobenzoate by UVA in human melanocytes but not in keratinocytes. Photochem Photobiol 73:600-4
55. Yamaguchi K, Lee SH, Eling TE, Baek SJ (2004) Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem 279:49617-23
56. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT (2003) Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2:1023-9